Immunic, Inc. Common Stock (IMUX) is a publicly traded Healthcare sector company. As of May 21, 2026, IMUX trades at $11.55 with a market cap of $158.83M and a P/E ratio of -17.70. IMUX moved -0.43% today. Year to date, IMUX is +81.26%; over the trailing twelve months it is +18.63%. Its 52-week range spans $5.06 to $17.30. Analyst consensus is strong buy with an average price target of $38.40. Rallies surfaces IMUX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Immunic Raises $200M, Appoints New CMO and Eyes MS Phase 3 Data: Immunic raised $200 million in an oversubscribed private placement, with potential for an additional $200 million, to fund its Phase 3 ENSURE trials and planned mid-2027 NDA submission. The company appointed Michael A. Panzara as Chief Medical Officer and expects top-line data from its Phase 3 ENSURE trials by year-end 2026.
| Metric | Value |
|---|---|
| Price | $11.55 |
| Market Cap | $158.83M |
| P/E Ratio | -17.70 |
| EPS | $-0.62 |
| Dividend Yield | 0.00% |
| 52-Week High | $17.30 |
| 52-Week Low | $5.06 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-97.17M |
| Gross Margin | 0.00% |
7 analysts cover IMUX: 0 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $38.40.